Predictors of clinically meaningful bone mineral density gains with romosozumab: An explainable machine leaning analysis of a real-world cohort.

ABSTRACT:

Objective

To evaluate the real-world effectiveness of Romosozumab in postmenopausal women with severe osteoporosis and to identify baseline clinical and biochemical predictors of clinically meaningful bone mineral density (BMD) gains (≥10 %, used for exploratory classification) using an explainable machine-learning approach.

Methods

We conducted a retrospective, observational multicentre study across seven hospitals in Castilla-La Mancha, Spain. Postmenopausal women aged ≥50 years who initiated romosozumab between May 2023 and November 2024 for severe osteoporosis or high fracture risk were included. Lumbar-spine, femoral-neck, and total-hip BMD were assessed by dual-energy X-ray absorptiometry (DXA) at baseline and 12 months. Baseline biochemical variables included serum P1

SUBMITTER: Corredor DC 

PROVIDER: S-EPMC12704072 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature